DAMAX Solutions recently led a multi-site clinical study aimed at evaluating the safety, accuracy, and effectiveness of the LIAISON® QuantiFERON®-TB Gold Plus assay, used with the LIAISON® analyzer family, for the diagnosis of active tuberculosis (TB) in high-burden settings.
📍 Study Locations
Dar es Salaam: 200 clients
Mwanza Region: 160 clients
👥 Participants
Clients aged 2 years and above, presenting with symptoms of active TB, and confirmed positive via GeneXpert®
🎯 Study Goal
To generate robust evidence on the assay’s clinical performance—supporting product labeling and validating its intended use for TB diagnosis in TB-endemic regions like Tanzania.
This study provides critical insights into the real-world application of advanced diagnostic tools and reinforces their potential in improving TB case detection. The findings contribute meaningfully to Tanzania’s efforts to modernize and scale up accurate, rapid, and accessible TB diagnosis.